Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Companyâs immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.

Employees

221

Sector

Pharmaceuticals

Calendar

07-31 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
12/06/25	0.7904 $	-1.80%	742,018
11/06/25	0.8049 $	-0.04%	894,848
10/06/25	0.8052 $	-5.76%	1,715,895
09/06/25	0.8544 $	+2.94%	1,773,911
06/06/25	0.8300 $	+3.02%	1,870,139

Delayed Quote Nasdaq, June 12, 2025 at 11:00 pm

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.7904USD

Average target price

4.683USD

Spread / Average Target

+492.53%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 23:00:00 12/06/2025 +03			5-day change	1st Jan Change
0.7904 ^USD	-1.80%		-1.90%	-42.72%

05-30	Coherus Completes Strategic Transformation To Coherus Oncology	RE
05-29	Coherus BioSciences, Inc., Q1 2025 Earnings Call, May 12, 2025

Capitalization	91.63M 79.17M 74.54M 67.45M 125M 7.85B 141M 866M 338M 3.61B 344M 337M 13.17B	P/E ratio 2025 *	-1.09x	P/E ratio 2026 *	-0.97x
Enterprise value	-14.31M -12.37M -11.64M -10.54M -19.49M -1.23B -21.95M -135M -52.81M -563M -53.7M -52.57M -2.06B	EV / Sales 2025 *	-0.24x	EV / Sales 2026 *	0.37x
Free-Float	95.98%	Yield 2025 *	-	Yield 2026 *	-

Coherus Completes Strategic Transformation To Coherus Oncology	05-30	RE
Coherus BioSciences, Inc., Q1 2025 Earnings Call, May 12, 2025	05-29
Coherus BioSciences, Inc. has Changed its Name to Coherus Oncology, Inc	05-29	CI
Coherus BioSciences, Inc. Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI®? (toripalimab-Ttzi)	05-27	CI
Storm Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate Stc-15 in Combination with Loqtorzi®?	05-27	CI
Coherus BioSciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	05-12	CI
Coherus BioSciences, Inc. - Shareholder/Analyst Call	04-28
Coherus BioSciences Phase 1 Trial of CHS-114 Shows Confirmed Partial Response in Cancer Patient	04-28	MT
Coherus Presents Early Clinical Data from Phase 1 Dose Expansion Study of CHS-114 in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma At AACR 2025	04-28	CI
Coherus Biosciences, Inc. Announces Board Changes	04-25	CI
Coherus Biosciences, Inc. Announces Resignation of Paul Reider as Chief Commercial Officer, Effective April 30 2025	04-23	CI
Sector Update: Health Care Stocks Rise Late Afternoon	04-14	MT
Sector Update: Health Care	04-14	MT

UBS Downgrades Coherus BioSciences to Neutral From Buy, Adjusts Price Target to $1.50 From $4	16/08/24	MT
Baird Trims Price Target on Coherus BioSciences to $8 From $9, Maintains Outperform Rating	01/07/24	MT
Truist Securities Trims Price Target on Coherus BioSciences to $7 From $8, Maintains Buy Rating	13/05/24	MT
HC Wainwright Adjusts Coherus BioSciences' Price Target to $11 From $13, Keeps Buy Rating	20/03/24	MT
Baird Cuts Coherus BioSciences' Price Target to $9 From $11, Outperform Rating Maintained	23/01/24	MT

Coherus Oncology, Inc. Stock

Equities

CHRS

US19249H1032

Pharmaceuticals

Valuation: Coherus Oncology, Inc.

Chart: Coherus Oncology, Inc.

Latest news: Coherus Oncology, Inc.

Last Transcript: Coherus Oncology, Inc.

Analysts' recommendations: Coherus Oncology, Inc.

Press Releases: Coherus Oncology, Inc.

News in other languages: Coherus Oncology, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Coherus Oncology, Inc.

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics	05-30	GL
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)	05-27	GL
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi)	05-27	AQ
Coherus BioSciences: Q1 Earnings Snapshot	05-12	AQ
Coherus BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update	05-12	AQ

Novavax, Insulet, Moderna... Les valeurs à suivre aujourd'hui à Wall Street	10/05/24
Coherus BioSciences : réduit sa perte au 1er trimestre, mais déçoit les investisseurs	10/05/24
Coherus Biosciences : Delta Airlines, KKR...les valeurs à suivre aujourd'hui à Wall Street -	14/03/24
Coherus Biosciences : trébuche au quatrième trimestre	14/03/24
Bourse Zurich: le SMI ne parvient pas à remonter la pente	04/03/24

1 day	-1.80%
1 week	-1.90%
Current month	+1.46%
1 month	-22.51%
3 months	-19.35%
6 months	-47.31%
Current year	-42.72%

1 week	0.76	0.9
1 month	0.71	0.9
Current year	0.71	1.77
1 year	0.66	2.43
3 years	0.66	14.11
5 years	0.66	22.22
10 years	0.66	38.1

Manager	Title	Age	Since
Denny Lanfear CEO	Chief Executive Officer	69	01/09/2010
Bryan Mcmichael DFI	Director of Finance/CFO	47	08/12/2023
Rosh Dias CTO	Chief Tech/Sci/R&D Officer	-	15/03/2022

Director	Title	Age	Since
Mats Wahlström BRD	Director/Board Member	70	01/01/2012
Denny Lanfear CHM	Chairman	69	01/09/2010
Ali Satvat BRD	Director/Board Member	47	01/05/2014

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
COHERUS ONCOLOGY, INC.	-1.80%	-1.90%	-56.57%	-88.24%	93.31M
ELI LILLY AND COMPANY	+0.42%	+6.05%	-6.37%	+173.40%	726B
JOHNSON & JOHNSON	+0.90%	+1.95%	+7.74%	-9.21%	374B
NOVO NORDISK A/S	+0.48%	+8.92%	-47.53%	+32.18%	353B
ABBVIE INC.	+0.48%	+2.64%	+15.85%	+34.37%	338B
ROCHE HOLDING AG	+1.00%	+1.83%	+11.95%	-13.17%	264B
NOVARTIS AG	+1.10%	+1.45%	+3.60%	+16.86%	232B
ASTRAZENECA PLC	+1.14%	+3.08%	-11.52%	+11.97%	229B
MERCK & CO., INC.	+1.87%	+5.41%	-37.16%	-6.15%	202B
AMGEN INC.	+1.88%	+3.55%	-1.26%	+23.87%	157B
Average	+0.60%	+2.36%	-12.13%	+17.59%	287.48B
Weighted average by Cap.	+0.59%	+3.63%	-6.78%	+52.56%

	2025 *	2026 *
Net sales	59.57M 51.46M 48.45M 43.84M 81.11M 5.1B 91.35M 563M 220M 2.34B 223M 219M 8.56B	99.46M 85.93M 80.9M 73.21M 135M 8.52B 153M 940M 367M 3.91B 373M 365M 14.3B
Net income	-160M -138M -130M -118M -218M -13.72B -246M -1.51B -591M -6.3B -601M -588M -23.03B	-99.85M -86.27M -81.22M -73.5M -136M -8.55B -153M -944M -368M -3.93B -375M -367M -14.35B
Net Debt	-106M -91.54M -86.18M -77.98M -144M -9.07B -162M -1B -391M -4.17B -397M -389M -15.23B	-55.32M -47.79M -45M -40.72M -75.32M -4.74B -84.83M -523M -204M -2.18B -208M -203M -7.95B